We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$145M
AUM Growth
-$11.5M
Cap. Flow
-$8.89M
Cap. Flow %
-6.13%
Top 10 Hldgs %
82.11%
Holding
47
New
8
Increased
4
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$1.65M
2
JBIO
Jade Biosciences
JBIO
+$1.05M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$836K
4
REPL icon
Replimune Group
REPL
+$709K
5
TVTX icon
Travere Therapeutics
TVTX
+$543K

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$7.82M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$3.42M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.85M
4
TRDA icon
Entrada Therapeutics
TRDA
+$1.19M
5
TSVT
2seventy bio
TSVT
+$586K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$44.3M 30.56%
225,688
-15,951
-7% -$3.42M
ILMN icon
2
Illumina
ILMN
$31B
$24.1M 16.61%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.08B
$20.3M 14%
368,665
-142,313
-28% -$7.82M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$6.05M 4.17%
47,096
– –
REPL icon
5
Replimune Group
REPL
$5.15M 3.55%
189,339
+34,140
+22% +$709K
EXAI
6
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.55M 3.13%
853,050
– –
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.2B
$4.51M 3.11%
114,380
– –
SLGC
8
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.26M 2.93%
1,696,558
– –
KDNY
9
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.99M 2.06%
113,950
– –
RANI icon
10
Rani Therapeutics
RANI
$92.2M
$2.91M 2.01%
493,584
– –
INCY icon
11
Incyte
INCY
$24.9B
$2.76M 1.9%
34,391
– –
ONC
12
BeOne Medicines Ltd
ONC
$33.4B
$2.64M 1.82%
12,022
– –
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.4M 1.65%
111,984
– –
EAR
14
DELISTED
Eargo, Inc. Common Stock
EAR
$1.7M 1.17%
147,905
+3,569
+2% +$45.9K
BOLT icon
15
Bolt Biotherapeutics
BOLT
$7.47M
$1.52M 1.05%
58,348
– –
JBIO
16
Jade Biosciences
JBIO
$1.22B
$1.48M 1.02%
+1,446
New +$1.05M
MRUS
17
DELISTED
Merus
MRUS
$1.45M 1%
+93,750
New +$1.65M
PACB icon
18
Pacific Biosciences
PACB
$460M
$1.12M 0.77%
136,655
-8,185
-6% -$70.5K
EXEL icon
19
Exelixis
EXEL
$14.1B
$1.03M 0.71%
64,200
– –
TRDA icon
20
Entrada Therapeutics
TRDA
$263M
$995K 0.69%
73,582
-68,011
-48% -$1.19M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7.25B
$947K 0.65%
+32,520
New +$836K
GRTX
22
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$914K 0.63%
613,223
– –
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.7B
$633K 0.44%
6,115
– –
DBVT
24
DBV Technologies
DBVT
$817M
$568K 0.39%
37,095
– –
KYNB
25
Kyntra Bio
KYNB
$27.5M
$546K 0.38%
1,364
+774
+131% +$296K
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q4 2022 Portfolio in Review

As of Q4 2022, Nan Fung Group Holdings held 47 positions worth $145M, down 7.4% from $157M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Nan Fung Group Holdings withdrew a net $8.89M in Q4 2022, closing 5 positions and reducing 4 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $1.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Merus worth $1.45M.

  • Nan Fung Group Holdings's largest Q4 2022 buy was Merus: 93,750 shares worth $1.45M.
  • Nan Fung Group Holdings added most to Replimune Group in Q4 2022, an estimated $709K increase.
  • Nan Fung Group Holdings's biggest Q4 2022 reduction was Harmony Biosciences, cutting an estimated $7.82M.
  • Nan Fung Group Holdings fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $1.85M.
  • Nan Fung Group Holdings's ten largest holdings make up 82% of its $145M portfolio in Q4 2022.
  • Nan Fung Group Holdings opened 8 new positions and closed 5 in Q4 2022.
  • Nan Fung Group Holdings's portfolio value fell 7.4% quarter-over-quarter to $145M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2022, filed 13 Feb 2023.